Quotient Sciences Quotient Sciences

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"CytRx Corporation","sponsor":"ImmunityBio","pharmaFlowCategory":"D","amount":"$343.0 million","upfrontCash":"Undisclosed","newsHeadline":"CytRx Corporation Highlights Significant Positive Events From its Licensed Drug Aldoxorubicin","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I"},{"orgOrder":0,"company":"CytRx Corporation","sponsor":"Orphazyme","pharmaFlowCategory":"D","amount":"$120.0 million","upfrontCash":"Undisclosed","newsHeadline":"CytRx Corporation Highlights Updated Arimoclomol Milestone Guidance","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III"},{"orgOrder":0,"company":"CytRx Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CytRx Corporation Highlights Latest Positive Event From its Licensed Drug Aldoxorubicin","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II"},{"orgOrder":0,"company":"CytRx Corporation","sponsor":"Orphazyme","pharmaFlowCategory":"D","amount":"$83.7 million","upfrontCash":"Undisclosed","newsHeadline":"CytRx Issues Statement Regarding Orphazyme\u2019s Global Offering","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III"},{"orgOrder":0,"company":"CytRx Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CytRx Highlights Use of Licensed Drug Aldoxorubicin in Treatment of Former Senate Majority Leader Harry Reid\u2019s Pancreatic Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II"},{"orgOrder":0,"company":"CytRx Corporation","sponsor":"ImmunityBio","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CytRx Highlights Use of Licensed Drug Aldoxorubicin in ImmunityBio\u2019s Expanded Phase 2 Study of Pancreatic Cancer Treatment","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II"},{"orgOrder":0,"company":"CytRx Corporation","sponsor":"NantKwest","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CytRx Reports Use of Aldoxorubicin in Phase 2 Clinical Trials Yielding Positive Interim Data on Survival Rates in Pancreatic Cancer Patients","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2021","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II"},{"orgOrder":0,"company":"CytRx Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CytRx Notes Orphazyme\u2019s Regulatory Update from the FDA on Arimoclomol","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II\/ Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III"},{"orgOrder":0,"company":"CytRx Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CytRx Comments on Orphazyme\u2019s Promising 24-Month Interim Trial Results of Arimoclomol for Niemann-Pick Disease Type C","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II\/ Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III"},{"orgOrder":0,"company":"CytRx Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CytRx Highlights Preliminary Results of Cohort C of QUILT 88","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2021","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II"},{"orgOrder":0,"company":"CytRx Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CytRx Highlights Orphazyme\u2019s Published Results From Its Phase 2\/3 Trial of Arimoclomol in Niemann-Pick Disease Type C","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II\/ Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2021","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III"},{"orgOrder":0,"company":"CytRx Corporation","sponsor":"ImmunityBio","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CytRx Highlights ImmunityBio's Completion of Enrollment in Phase 2 Study of Advanced Metastatic Pancreatic Cancer Treatment","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2021","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II"},{"orgOrder":0,"company":"CytRx Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CytRx Highlights ImmunityBio's Use of Aldoxorubicin in Ongoing Clinical Studies for Various Forms of Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2021","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II"},{"orgOrder":0,"company":"CytRx Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CytRx Highlights Orphazyme's Update on Planned NDA Resubmission for Arimoclomol in Niemann-Pick Disease Type C","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II\/ Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2022","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III"},{"orgOrder":0,"company":"CytRx Corporation","sponsor":"CytRx Corporation","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"CytRx Announces Integration of Wholly Owned Subsidiary Centurion BioPharma and Corporate Governance Updates","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III"},{"orgOrder":0,"company":"CytRx Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CytRx Partners with Oncology Development Expert to Advance LADR Platform","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III"}]

    Find Clinical Drug Pipeline Developments & Deals by CytRx Corporation

    Menu

    CytRx Corporation

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    APIs // Active Pharmaceutical Ingredients

    DEVELOPMENTS

    EXCIPIENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              CytRx Corporation

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              CytRx Partners with Oncology Development Expert to Advance LADR Platform

              Details:

              Aldoxorubicin, a rationally-engineered cytotoxic delivers well-established anti-cancer agent, doxorubicin, into tumor, utilizes an acid-sensitive linker that selectively binds to albumin, which may allow cytotoxic payload to preferentially accumulate in tumor.

              Lead Product(s): Aldoxorubicin

              Therapeutic Area: Oncology Product Name: INNO-206

              Highest Development Status: Phase III Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable April 20, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              CytRx Corporation

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              CytRx Announces Integration of Wholly Owned Subsidiary Centurion BioPharma and Corporate Governance Updates

              Details:

              Through the merger with Centurion, the next-generation LADR drugs including INNO-206, are now within CytRx and poised for the last steps required for first-in-human studies, an achievement that could be expected to generate significant value for shareholders.

              Lead Product(s): Aldoxorubicin

              Therapeutic Area: Oncology Product Name: INNO-206

              Highest Development Status: Phase III Product Type: Small molecule

              Recipient: Centurion BioPharma

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Merger March 09, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              CytRx Corporation

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              CytRx Highlights Orphazyme's Update on Planned NDA Resubmission for Arimoclomol in Niemann-Pick Disease Type C

              Details:

              CytRx’s drug candidate, arimoclomol, was sold to Orphazyme A/S in exchange for milestone payments and royalties. Orphazyme is developing arimoclomol in two indications, including Niemann-Pick disease Type C (NPC), and Gaucher disease.

              Lead Product(s): Arimoclomol

              Therapeutic Area: Genetic Disease Product Name: Undisclosed

              Highest Development Status: Phase II/ Phase III Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable February 14, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              CytRx Corporation

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              CytRx Highlights ImmunityBio's Use of Aldoxorubicin in Ongoing Clinical Studies for Various Forms of Cancer

              Details:

              ImmunityBio continues to study the effectiveness of N-803 and aldoxorubicin in combination with PD-L1 thaNK in Phase 1 / 2 clinical trials to treat triple negative breast cancer and head and neck cancer.

              Lead Product(s): Aldoxorubicin HCl,PD-L1 t-haNK,Paclitaxel

              Therapeutic Area: Oncology Product Name: Undisclosed

              Highest Development Status: Phase II Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable December 21, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              CytRx Corporation

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              CytRx Highlights ImmunityBio's Completion of Enrollment in Phase 2 Study of Advanced Metastatic Pancreatic Cancer Treatment

              Details:

              Phase 2, study will evaluate the comparative efficacy and safety of standard-of-care chemotherapy versus standard-of-care chemotherapy, in combination with PD-L1 t-haNK, Anktiva (N-803), and aldoxorubicin in subjects with locally advanced or metastatic pancreatic cancer.

              Lead Product(s): Aldoxorubicin HCl,Paclitaxel,Gemcitabine

              Therapeutic Area: Oncology Product Name: Undisclosed

              Highest Development Status: Phase II Product Type: Small molecule

              Recipient: ImmunityBio

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable October 13, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              CytRx Corporation

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              CytRx Highlights Orphazyme’s Published Results From Its Phase 2/3 Trial of Arimoclomol in Niemann-Pick Disease Type C

              Details:

              At 12-months, a significant treatment effect in favor of arimoclomol of −1.40 points was observed, corresponding to a 65% relative reduction in annual disease progression.

              Lead Product(s): Arimoclomol

              Therapeutic Area: Genetic Disease Product Name: Miplyffa

              Highest Development Status: Phase II/ Phase III Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable August 24, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              CytRx Corporation

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              CytRx Highlights Preliminary Results of Cohort C of QUILT 88

              Details:

              Enrollment of Cohort C, which includes Aldoxorubicin and patients who have previously failed two lines of standard-of-care therapy, is expected to be completed in the third quarter of 2021 and an early readout of survival data is expected in the first quarter of 2022.

              Lead Product(s): Aldoxorubicin HCl,Paclitaxel,Avelumab

              Therapeutic Area: Oncology Product Name: Undisclosed

              Highest Development Status: Phase II Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable July 29, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              CytRx Corporation

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              CytRx Comments on Orphazyme’s Promising 24-Month Interim Trial Results of Arimoclomol for Niemann-Pick Disease Type C

              Details:

              Orphazyme stated arimoclomol demonstrated a consistent safety profile throughout the 36-month treatment period. Arimoclomol is an investigational drug candidate that amplifies the production of heat-shock proteins (HSPs).

              Lead Product(s): Arimoclomol

              Therapeutic Area: Genetic Disease Product Name: Miplyffa

              Highest Development Status: Phase II/ Phase III Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable June 29, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              CytRx Corporation

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              CytRx Notes Orphazyme’s Regulatory Update from the FDA on Arimoclomol

              Details:

              CytRx has received a Complete Response Letter from the U.S. Food and Drug Administration following its review of the new drug application for arimoclomol, a heat shock protein amplifier intended for the treatment of Niemann-Pick disease type C.

              Lead Product(s): Arimoclomol

              Therapeutic Area: Genetic Disease Product Name: Miplyffa

              Highest Development Status: Phase II/ Phase III Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable June 18, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              CytRx Corporation

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              CytRx Reports Use of Aldoxorubicin in Phase 2 Clinical Trials Yielding Positive Interim Data on Survival Rates in Pancreatic Cancer Patients

              Details:

              NantKwest and ImmunityBio’s QUILT 88 Trial shows novel combination immunotherapy, which includes which include CytRx’s licensed drug aldoxorubicin, has more than doubled historic median survival rates in patients.

              Lead Product(s): Aldoxorubicin HCl,PD-L1 t-haNK,Paclitaxel

              Therapeutic Area: Oncology Product Name: Undisclosed

              Highest Development Status: Phase II Product Type: Small molecule

              Partner/Sponsor/Collaborator: NantKwest

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable January 15, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.
              Aspen API. More than just an API.
              Post Enquiry
              POST ENQUIRY